These molecules, integrated into the membranes of recipient cells, significantly enhance antigen presentation efficiency in EBV-infected tumor cells for both tumor and viral antigens, thereby effectively activating CD4+-T-cell-mediated helper immune responses and CD8+-T-cell-specific cytotoxic functions.34 This evidence concerns the gene CD8A and neoplasm.